GlassScriptPhysician profile
Louis Sithu
NPI 1306318225
$6,128.47
in general payments reported to CMS, 2019-2025
50 companies · $27.29 in 2025
The $27.29 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,140 · 2022: $3,879 · 2023: $848 · 2024: $234 · 2025: $27.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $775.56 | 2021-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $590.81 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $405.83 | 2021-2023 | Opdivo |
| Incyte Corporation | $335.20 | 2021-2022 | |
| Beigene USA, INC. | $302.37 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $283.47 | 2022-2023 | Imbruvica |
| Celgene Corporation | $218.95 | 2021-2023 | Pomalyst |
| Astellas Pharma US INC | $206.18 | 2022 | |
| Daiichi Sankyo INC. | $165.84 | 2022-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $164.99 | 2022-2023 | Enhertu |
| Glaxosmithkline, LLC. | $163.14 | 2021-2023 | Zejula |
| Rigel Pharmaceuticals, INC. | $158.48 | 2021-2022 | |
| Pfizer INC. | $153.91 | 2021-2023 | |
| Eisai INC. | $139.91 | 2022-2024 | |
| Genzyme Corporation | $130.76 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Sithu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.